AbbVie and Other Drugmakers Reach Price Reduction Agreements with U.S. Government
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy ABBV?
Source: Newsfilter
- Price Reduction Agreements: AbbVie, Bristol Myers Squibb, Gilead, and other drugmakers are expected to announce agreements with the U.S. government on Friday to lower certain prescription drug prices, aiming to address the high drug costs in the U.S., which could impact these companies' revenue structures.
- Market Response Stabilized: Although the U.S. government may implement stricter drug price controls, the agreements reached so far have alleviated investor concerns, demonstrating the market's adaptability to drug pricing reforms.
- Impact on Medicaid Spending: Analysts note that while Medicaid accounts for only about 10% of U.S. drug spending, its price discounts exceed 80% in some cases, which may influence drugmakers' pricing strategies and profit margins.
- Industry Dynamics Shift: As more drug companies negotiate with the government, price competition within the industry is expected to intensify, potentially leading to an overall decline in profit levels in the drug market, prompting companies to reassess their market positioning and strategic direction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 225.370
Low
223.00
Averages
252.00
High
289.00
Current: 225.370
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Concorde Financial Fully Liquidates Howard Hughes Holdings Stake
- Liquidation Transaction: Concorde Financial Corp disclosed in an SEC filing dated February 17, 2026, that it fully liquidated its stake in Howard Hughes Holdings, selling 52,047 shares for approximately $4.28 million, indicating a cautious outlook on the company's future performance.
- Position Change: Prior to the liquidation, Howard Hughes Holdings represented 2.4% of Concorde Financial's assets under management, with the firm reallocating its focus to other assets such as JPM and XOM, which now account for 7.1% and 6.2% of AUM, respectively.
- Market Performance: As of February 16, 2026, Howard Hughes Holdings shares were priced at $82.15, reflecting a 9.5% increase over the past year, yet underperforming the S&P 500 by 2.3 percentage points, highlighting its relative weakness in the market.
- Investor Considerations: Howard Hughes Holdings operates on a long-cycle real estate development model, and while it controls significant land in fast-growing markets, the ability to consistently convert land ownership into stable commercial income remains a critical concern for investors.
See More
Concorde Financial Completely Exits Howard Hughes Holdings
- Complete Liquidation: Concorde Financial Corp has fully liquidated its position in Howard Hughes Holdings by selling 52,047 shares for an estimated $4.28 million, reflecting trading activity and share price fluctuations based on quarterly average pricing.
- Asset Decline: This transaction resulted in a $4.28 million reduction in Concorde Financial's reportable assets under management, representing a 3.3% decrease, indicating a complete exit from its investment in Howard Hughes.
- Position Change: Prior to the sale, Howard Hughes Holdings constituted 2.4% of Concorde Financial's assets under management, and now the firm holds zero shares, highlighting a significant shift in its investment strategy.
- Market Performance: As of February 16, 2026, Howard Hughes Holdings shares were priced at $82.15, reflecting a 9.5% increase over the past year, yet underperforming the S&P 500 by 2.3 percentage points, suggesting a lack of confidence in the company's future prospects.
See More
Top Dividend Stocks to Buy: J&J and AbbVie
- Strong Dividend Growth: Johnson & Johnson, a Dividend King, has raised its dividends for 50 consecutive years, reflecting its stable financial health and long-term investment appeal, with future sales expected to grow despite challenges from patent expirations and government price negotiations.
- Diversified Product Portfolio: Johnson & Johnson boasts a wide range of products across pharmaceuticals and medical devices, with ongoing innovations helping it maintain a competitive edge, and the recently launched Ottava robotic-assisted surgery device is anticipated to further drive revenue growth.
- Consistent Dividend Returns: AbbVie has increased its dividends for 54 straight years since going public in 2013, showcasing its strong profitability and stable cash flow, particularly with impressive performance in its immunology and oncology product lines, making it an ideal choice for long-term investors.
- Innovative Capability and Market Adaptability: AbbVie quickly returned to revenue growth after losing Humira's patent, demonstrating its robust innovation capabilities, and is expected to be well-prepared to address patent expirations in the 2030s, ensuring its long-term dividend payment capacity.
See More
Investment Opportunities Amid Market Volatility
- AbbVie's Defensive Nature: AbbVie boasts a vast portfolio of medicines, and despite economic downturns, the demand for therapies addressing chronic autoimmune diseases and cancer remains strong, ensuring stable revenue and earnings, thus providing investors with a sense of security during market declines.
- AbbVie's Dividend King Status: As a Dividend King with 50 consecutive years of dividend increases, AbbVie demonstrates its ability to maintain dividend payments even in tough economic times, helping investors smooth out losses and enhancing its appeal amid market volatility.
- Microsoft's Stable Revenue: Although Microsoft operates in a cyclical industry, its office software products are integral to daily life for individuals and businesses, allowing it to maintain a steady revenue stream even during economic recessions, showcasing the resilience of its business model.
- Growth Potential in Cloud and AI: Microsoft's leadership in cloud computing and artificial intelligence provides strong growth prospects, and while it may face challenges during economic slowdowns, investors can still expect superior returns in the long run, making it an attractive investment opportunity.
See More
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial
- Clinical Trial Success: UCB's Bimzelx achieved the primary endpoint ACR50 in the BE BOLD trial for psoriatic arthritis, demonstrating over 50% improvement and indicating its superiority over AbbVie's Skyrizi, which could significantly enhance UCB's competitive position in the biopharmaceutical market.
- Patient Recruitment: The trial enrolled over 500 adults with active psoriatic arthritis, ensuring the reliability and broad applicability of the data, thereby strengthening Bimzelx's market recognition as an effective treatment option.
- Good Safety Profile: UCB reported that Bimzelx has a well-tolerated safety profile with no new safety signals, providing strong support for its market promotion and patient acceptance, which may drive future sales growth.
- Broad Market Prospects: This trial marks the fourth head-to-head study showing Bimzelx's superiority in psoriatic disease and the first in PsA, indicating UCB's ongoing innovation capabilities and market potential in this therapeutic area.
See More
Dublin Data Center First to Use Independent Microgrid in Europe
- Microgrid Innovation: The Dublin facility, a collaboration between AVK and Pure Data Centre Group, establishes Europe's first independent microgrid data center with an estimated total investment of €1 billion, aimed at addressing power connection delays and promoting sustainable development in data centers.
- Rising Energy Demand: The European Commission estimates that by 2040, at least €1.2 trillion will be needed to meet growing energy demands, with data centers consuming 22% of Ireland's power in 2024, highlighting their pressure on the national grid.
- Policy Changes Impact: The Irish government has eased the moratorium on new data center applications, mandating that new facilities provide dispatchable power or energy storage capacity, which promotes the adoption of microgrids and reflects a reassessment of the AI industry's potential.
- Market Growth Potential: The global microgrid market is projected to reach $29 billion by 2025, with Europe's market expected to grow nearly 10% annually, providing new investment opportunities for companies like AVK and driving technological advancements in the data center sector.
See More
Concorde Financial Fully Liquidates Howard Hughes Holdings Stake
- Liquidation Transaction: Concorde Financial Corp disclosed in an SEC filing dated February 17, 2026, that it fully liquidated its stake in Howard Hughes Holdings, selling 52,047 shares for approximately $4.28 million, indicating a cautious outlook on the company's future performance.
- Position Change: Prior to the liquidation, Howard Hughes Holdings represented 2.4% of Concorde Financial's assets under management, with the firm reallocating its focus to other assets such as JPM and XOM, which now account for 7.1% and 6.2% of AUM, respectively.
- Market Performance: As of February 16, 2026, Howard Hughes Holdings shares were priced at $82.15, reflecting a 9.5% increase over the past year, yet underperforming the S&P 500 by 2.3 percentage points, highlighting its relative weakness in the market.
- Investor Considerations: Howard Hughes Holdings operates on a long-cycle real estate development model, and while it controls significant land in fast-growing markets, the ability to consistently convert land ownership into stable commercial income remains a critical concern for investors.
See More
Concorde Financial Completely Exits Howard Hughes Holdings
- Complete Liquidation: Concorde Financial Corp has fully liquidated its position in Howard Hughes Holdings by selling 52,047 shares for an estimated $4.28 million, reflecting trading activity and share price fluctuations based on quarterly average pricing.
- Asset Decline: This transaction resulted in a $4.28 million reduction in Concorde Financial's reportable assets under management, representing a 3.3% decrease, indicating a complete exit from its investment in Howard Hughes.
- Position Change: Prior to the sale, Howard Hughes Holdings constituted 2.4% of Concorde Financial's assets under management, and now the firm holds zero shares, highlighting a significant shift in its investment strategy.
- Market Performance: As of February 16, 2026, Howard Hughes Holdings shares were priced at $82.15, reflecting a 9.5% increase over the past year, yet underperforming the S&P 500 by 2.3 percentage points, suggesting a lack of confidence in the company's future prospects.
See More
Top Dividend Stocks to Buy: J&J and AbbVie
- Strong Dividend Growth: Johnson & Johnson, a Dividend King, has raised its dividends for 50 consecutive years, reflecting its stable financial health and long-term investment appeal, with future sales expected to grow despite challenges from patent expirations and government price negotiations.
- Diversified Product Portfolio: Johnson & Johnson boasts a wide range of products across pharmaceuticals and medical devices, with ongoing innovations helping it maintain a competitive edge, and the recently launched Ottava robotic-assisted surgery device is anticipated to further drive revenue growth.
- Consistent Dividend Returns: AbbVie has increased its dividends for 54 straight years since going public in 2013, showcasing its strong profitability and stable cash flow, particularly with impressive performance in its immunology and oncology product lines, making it an ideal choice for long-term investors.
- Innovative Capability and Market Adaptability: AbbVie quickly returned to revenue growth after losing Humira's patent, demonstrating its robust innovation capabilities, and is expected to be well-prepared to address patent expirations in the 2030s, ensuring its long-term dividend payment capacity.
See More
Investment Opportunities Amid Market Volatility
- AbbVie's Defensive Nature: AbbVie boasts a vast portfolio of medicines, and despite economic downturns, the demand for therapies addressing chronic autoimmune diseases and cancer remains strong, ensuring stable revenue and earnings, thus providing investors with a sense of security during market declines.
- AbbVie's Dividend King Status: As a Dividend King with 50 consecutive years of dividend increases, AbbVie demonstrates its ability to maintain dividend payments even in tough economic times, helping investors smooth out losses and enhancing its appeal amid market volatility.
- Microsoft's Stable Revenue: Although Microsoft operates in a cyclical industry, its office software products are integral to daily life for individuals and businesses, allowing it to maintain a steady revenue stream even during economic recessions, showcasing the resilience of its business model.
- Growth Potential in Cloud and AI: Microsoft's leadership in cloud computing and artificial intelligence provides strong growth prospects, and while it may face challenges during economic slowdowns, investors can still expect superior returns in the long run, making it an attractive investment opportunity.
See More
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial
- Clinical Trial Success: UCB's Bimzelx achieved the primary endpoint ACR50 in the BE BOLD trial for psoriatic arthritis, demonstrating over 50% improvement and indicating its superiority over AbbVie's Skyrizi, which could significantly enhance UCB's competitive position in the biopharmaceutical market.
- Patient Recruitment: The trial enrolled over 500 adults with active psoriatic arthritis, ensuring the reliability and broad applicability of the data, thereby strengthening Bimzelx's market recognition as an effective treatment option.
- Good Safety Profile: UCB reported that Bimzelx has a well-tolerated safety profile with no new safety signals, providing strong support for its market promotion and patient acceptance, which may drive future sales growth.
- Broad Market Prospects: This trial marks the fourth head-to-head study showing Bimzelx's superiority in psoriatic disease and the first in PsA, indicating UCB's ongoing innovation capabilities and market potential in this therapeutic area.
See More
Dublin Data Center First to Use Independent Microgrid in Europe
- Microgrid Innovation: The Dublin facility, a collaboration between AVK and Pure Data Centre Group, establishes Europe's first independent microgrid data center with an estimated total investment of €1 billion, aimed at addressing power connection delays and promoting sustainable development in data centers.
- Rising Energy Demand: The European Commission estimates that by 2040, at least €1.2 trillion will be needed to meet growing energy demands, with data centers consuming 22% of Ireland's power in 2024, highlighting their pressure on the national grid.
- Policy Changes Impact: The Irish government has eased the moratorium on new data center applications, mandating that new facilities provide dispatchable power or energy storage capacity, which promotes the adoption of microgrids and reflects a reassessment of the AI industry's potential.
- Market Growth Potential: The global microgrid market is projected to reach $29 billion by 2025, with Europe's market expected to grow nearly 10% annually, providing new investment opportunities for companies like AVK and driving technological advancements in the data center sector.
See More
